Cara Therapeutics, Inc.

NasdaqCM:CARA 株式レポート

時価総額:US$16.7m

Cara Therapeutics 将来の成長

Future 基準チェック /26

Cara Therapeuticsは、37.3%と46.4%でそれぞれ年率37.3%で利益と収益が成長すると予測される一方、EPSはgrowで53.1%年率。

主要情報

37.3%

収益成長率

53.1%

EPS成長率

Pharmaceuticals 収益成長23.8%
収益成長率46.4%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日11 Nov 2024

今後の成長に関する最新情報

Recent updates

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues

Nov 01
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jul 18
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

May 29
We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

May 25
Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Feb 16
We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

Dec 19
The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

Nov 04
News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Oct 25
Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Jul 20
Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

Jun 04
Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Mar 11
News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

Feb 15
Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

Feb 06
We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Oct 18
We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients

Sep 28

Cara Therapeutics hires new finance chief

Sep 12

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Sep 01

Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients

Aug 19

Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M

Aug 08

Calls A Much Safer Way To Buy Cara Therapeutics

Jun 24

We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Jun 15
We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

May 12
Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

Taking A (Speculative) Position In Cara Therapeutics

Mar 21

Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

Mar 09
Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

Cara Therapeutics: De-Risked And Extremely Attractive

Dec 25

Checking Back In On Cara Therapeutics

Nov 01

Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA

Aug 21

The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically

Aug 15
The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically

Cara Therapeutics: 200% Upside Possible With FDA Approval

Aug 11

業績と収益の成長予測

NasdaqCM:CARA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20267-37N/A-363
12/31/20256-46N/A-523
12/31/20247-74N/A-633
9/30/20249-96-77-74N/A
6/30/202411-111-83-80N/A
3/31/202417-123-91-88N/A
12/31/202321-119-94-92N/A
9/30/202321-117-99-98N/A
6/30/202327-112-104-104N/A
3/31/202343-84-88-88N/A
12/31/202242-85-79-79N/A
9/30/202239-89-57-56N/A
6/30/202249-66-45-45N/A
3/31/202226-93-62-62N/A
12/31/202123-88-60-60N/A
9/30/2021134242323N/A
6/30/202112381516N/A
3/31/20211291499N/A
12/31/20201358-6-5N/A
9/30/202028-99-119-119N/A
6/30/202024-115-123-123N/A
3/31/202024-113-120-120N/A
12/31/201920-106-109-109N/A
9/30/201921-98-102-102N/A
6/30/201920-85-97-97N/A
3/31/201918-79-31-31N/A
12/31/201813-74-22-22N/A
9/30/20188-68-9-9N/A
6/30/20183-61N/A1N/A
3/31/2018N/A-53N/A-52N/A
12/31/20171-58N/A-55N/A
9/30/20171-66N/A-57N/A
6/30/20171-65N/A-60N/A
3/31/20171-69N/A-59N/A
12/31/20160-57N/A-47N/A
9/30/20160-45N/A-38N/A
6/30/20163-38N/A-33N/A
3/31/20163-31N/A-26N/A
12/31/20154-25N/A-21N/A
9/30/20155-19N/A-23N/A
6/30/20153-21N/A-20N/A
3/31/20153-19N/A-20N/A
12/31/20143-18N/A-18N/A
9/30/20143-16N/A-17N/A
6/30/20143-14N/A-16N/A
3/31/201412-6N/A2N/A
12/31/201312-3N/A3N/A

アナリストによる今後の成長予測

収入対貯蓄率: CARA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CARA今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CARA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CARAの収益 ( 46.4% ) US市場 ( 9% ) よりも速いペースで成長すると予測されています。

高い収益成長: CARAの収益 ( 46.4% ) 20%よりも速いペースで成長すると予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: CARAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘